1
|
Singh S, Sarroza D, English A, Whittington D, Dong A, Malamas M, Makriyannis A, van der Stelt M, Li Y, Zweifel L, Bruchas MR, Land BB, Stella N. P2X 7 receptor-dependent increase in endocannabinoid 2-arachidonoyl glycerol production by neuronal cells in culture: Dynamics and mechanism. Br J Pharmacol 2024. [PMID: 38581262 DOI: 10.1111/bph.16348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2023] [Revised: 01/12/2024] [Accepted: 02/01/2024] [Indexed: 04/08/2024] Open
Abstract
BACKGROUND AND PURPOSE Neurotransmission and neuroinflammation are controlled by local increases in both extracellular ATP and the endocannabinoid 2-arachidonoyl glycerol (2-AG). While it is known that extracellular ATP stimulates 2-AG production in cells in culture, the dynamics and molecular mechanisms that underlie this response remain poorly understood. Detection of real-time changes in eCB levels with the genetically encoded sensor, GRABeCB2.0, can address this shortfall. EXPERIMENTAL APPROACH 2-AG and arachidonoylethanolamide (AEA) levels in Neuro2a (N2a) cells were measured by LC-MS, and GRABeCB2.0 fluorescence changes were detected using live-cell confocal microscopy and a 96-well fluorescence plate reader. KEY RESULTS 2-AG and AEA increased GRABeCB2.0 fluorescence in N2a cells with EC50 values of 81 and 58 nM, respectively; both responses were reduced by the cannabinoid receptor type 1 (CB1R) antagonist SR141617 and absent in cells expressing the mutant-GRABeCB2.0. ATP increased only 2-AG levels in N2a cells, as measured by LC-MS, and induced a transient increase in the GRABeCB2.0 signal within minutes primarily via activation of P2X7 receptors (P2X7R). This response was dependent on diacylglycerol lipase β activity, partially dependent on extracellular calcium and phospholipase C activity, but not controlled by the 2-AG hydrolysing enzyme, α/β-hydrolase domain containing 6 (ABHD6). CONCLUSIONS AND IMPLICATIONS Considering that P2X7R activation increases 2-AG levels within minutes, our results show how these molecular components are mechanistically linked. The specific molecular components in these signalling systems represent potential therapeutic targets for the treatment of neurological diseases, such as chronic pain, that involve dysregulated neurotransmission and neuroinflammation.
Collapse
Affiliation(s)
- Simar Singh
- Department of Pharmacology, University of Washington, Seattle, Washington, USA
| | - Dennis Sarroza
- Department of Pharmacology, University of Washington, Seattle, Washington, USA
| | - Anthony English
- Department of Pharmacology, University of Washington, Seattle, Washington, USA
| | - Dale Whittington
- Department of Medicinal Chemistry, University of Washington, Seattle, Washington, USA
| | - Ao Dong
- Peking University School of Life Sciences, PKU-IDG/McGovern Institute for Brain Research, Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China
| | - Michael Malamas
- Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts, USA
| | - Alexandros Makriyannis
- Center for Drug Discovery and Departments of Chemistry and Chemical Biology and Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts, USA
| | | | - Yulong Li
- Peking University School of Life Sciences, PKU-IDG/McGovern Institute for Brain Research, Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China
| | - Larry Zweifel
- Department of Pharmacology, University of Washington, Seattle, Washington, USA
- Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA
- Center for Cannabis Research, University of Washington, Seattle, Washington, USA
- Center for the Neurobiology of Addiction, Pain, and Emotion, University of Washington, Seattle, Washington, USA
| | - Michael R Bruchas
- Department of Pharmacology, University of Washington, Seattle, Washington, USA
- Center for Cannabis Research, University of Washington, Seattle, Washington, USA
- Center for the Neurobiology of Addiction, Pain, and Emotion, University of Washington, Seattle, Washington, USA
- Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, Washington, USA
| | - Benjamin B Land
- Department of Pharmacology, University of Washington, Seattle, Washington, USA
- Center for Cannabis Research, University of Washington, Seattle, Washington, USA
- Center for the Neurobiology of Addiction, Pain, and Emotion, University of Washington, Seattle, Washington, USA
| | - Nephi Stella
- Department of Pharmacology, University of Washington, Seattle, Washington, USA
- Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA
- Center for Cannabis Research, University of Washington, Seattle, Washington, USA
- Center for the Neurobiology of Addiction, Pain, and Emotion, University of Washington, Seattle, Washington, USA
| |
Collapse
|
2
|
Singh S, Sarroza D, English A, McGrory M, Dong A, Zweifel L, Land BB, Li Y, Bruchas MR, Stella N. Pharmacological Characterization of the Endocannabinoid Sensor GRAB eCB2.0. Cannabis Cannabinoid Res 2023. [PMID: 38064488 DOI: 10.1089/can.2023.0036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2023] Open
Abstract
Introduction: The endocannabinoids (eCBs), 2-arachidonoylglycerol (2-AG) and arachidonoyl ethanolamine (AEA), are produced by separate enzymatic pathways, activate cannabinoid (CB) receptors with distinct pharmacological profiles, and differentially regulate pathophysiological processes. The genetically encoded sensor, GRABeCB2.0, detects real-time changes in eCB levels in cells in culture and preclinical model systems; however, its activation by eCB analogues produced by cells and by phyto-CBs remains uncharacterized, a current limitation when interpreting changes in its response. This information could provide additional utility for the tool in in vivo pharmacology studies of phyto-CB action. Materials and Methods: GRABeCB2.0 was expressed in cultured HEK293 cells. Live cell confocal microscopy and high-throughput fluorescent signal measurements. Results: 2-AG increased GRABeCB2.0 fluorescent signal (EC50=85 nM), and the cannabinoid 1 receptor (CB1R) antagonist, SR141716 (SR1), decreased GRABeCB2.0 signal (IC50=3.3 nM), responses that mirror their known potencies at the CB1R. GRABeCB2.0 fluorescent signal also increased in response to AEA (EC50=815 nM), the eCB analogues 2-linoleoylglycerol and 2-oleoylglycerol (EC50=632 and 868 nM, respectively), Δ9-tetrahydrocannabinol (Δ9-THC), and Δ8-THC (EC50=1.6 and 2.0 μM, respectively), and the artificial CB1R agonist, CP55,940 (CP; EC50=82 nM); however their potencies were less than what has been described at CB1R. Cannabidiol (CBD) did not affect basal GRABeCB2.0 fluorescent signal and yet reduced the 2-AG stimulated GRABeCB2.0 responses (IC50=9.7 nM). Conclusions: 2-AG and SR1 modulate the GRABeCB2.0 fluorescent signal with EC50 values that mirror their potencies at CB1R, whereas AEA, eCB analogues, THC, and CP increase GRABeCB2.0 fluorescent signal with EC50 values significantly lower than their potencies at CB1R. CBD reduces the 2-AG response without affecting basal signal, suggesting that GRABeCB2.0 retains the negative allosteric modulator (NAM) property of CBD at CB1R. This study describes the pharmacological profile of GRABeCB2.0 to improve interpretation of changes in fluorescent signal in response to a series of known eCBs and CB1R ligands.
Collapse
Affiliation(s)
- Simar Singh
- Department of Pharmacology, Pain, and Emotion, School of Medicine, University of Washington, Seattle, Washington, USA
- Center for Cannabis Research, Pain, and Emotion, School of Medicine, University of Washington, Seattle, Washington, USA
- Center for the Neurobiology of Addiction, Pain, and Emotion, School of Medicine, University of Washington, Seattle, Washington, USA
| | - Dennis Sarroza
- Department of Pharmacology, Pain, and Emotion, School of Medicine, University of Washington, Seattle, Washington, USA
| | - Anthony English
- Department of Pharmacology, Pain, and Emotion, School of Medicine, University of Washington, Seattle, Washington, USA
- Center for Cannabis Research, Pain, and Emotion, School of Medicine, University of Washington, Seattle, Washington, USA
- Center for the Neurobiology of Addiction, Pain, and Emotion, School of Medicine, University of Washington, Seattle, Washington, USA
| | - Maya McGrory
- Department of Pharmacology, Pain, and Emotion, School of Medicine, University of Washington, Seattle, Washington, USA
| | - Ao Dong
- Peking University School of Life Sciences, PKU-IDG/McGovern Institute for Brain Research, Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China
| | - Larry Zweifel
- Department of Pharmacology, Pain, and Emotion, School of Medicine, University of Washington, Seattle, Washington, USA
- Center for Cannabis Research, Pain, and Emotion, School of Medicine, University of Washington, Seattle, Washington, USA
- Center for the Neurobiology of Addiction, Pain, and Emotion, School of Medicine, University of Washington, Seattle, Washington, USA
- Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Washington, Seattle, Washington, USA
| | - Benjamin B Land
- Department of Pharmacology, Pain, and Emotion, School of Medicine, University of Washington, Seattle, Washington, USA
- Center for Cannabis Research, Pain, and Emotion, School of Medicine, University of Washington, Seattle, Washington, USA
- Center for the Neurobiology of Addiction, Pain, and Emotion, School of Medicine, University of Washington, Seattle, Washington, USA
| | - Yulong Li
- Peking University School of Life Sciences, PKU-IDG/McGovern Institute for Brain Research, Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China
| | - Michael R Bruchas
- Department of Pharmacology, Pain, and Emotion, School of Medicine, University of Washington, Seattle, Washington, USA
- Center for Cannabis Research, Pain, and Emotion, School of Medicine, University of Washington, Seattle, Washington, USA
- Center for the Neurobiology of Addiction, Pain, and Emotion, School of Medicine, University of Washington, Seattle, Washington, USA
- Department of Anesthesiology, School of Medicine, University of Washington, Seattle, Washington, USA
| | - Nephi Stella
- Department of Pharmacology, Pain, and Emotion, School of Medicine, University of Washington, Seattle, Washington, USA
- Center for Cannabis Research, Pain, and Emotion, School of Medicine, University of Washington, Seattle, Washington, USA
- Center for the Neurobiology of Addiction, Pain, and Emotion, School of Medicine, University of Washington, Seattle, Washington, USA
- Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Washington, Seattle, Washington, USA
| |
Collapse
|
3
|
Singh S, Sarroza D, English A, McGrory M, Dong A, Zweifel L, Land BB, Li Y, Bruchas MR, Stella N. Pharmacological characterization of the endocannabinoid sensor GRAB eCB2.0. bioRxiv 2023:2023.03.03.531053. [PMID: 36945533 PMCID: PMC10028790 DOI: 10.1101/2023.03.03.531053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/11/2023]
Abstract
Introduction The endocannabinoids (eCBs), 2-arachidonoylglycerol (2-AG) and arachidonoyl ethanolamine (AEA), are produced by separate enzymatic pathways, activate cannabinoid receptors with distinct pharmacology, and differentially regulate pathophysiological processes. The genetically encoded sensor, GRABeCB2.0, detects real-time changes in eCB levels in cells in culture and preclinical model systems; however, its activation by eCB analogues produced by cells and by phyto-cannabinoids remains uncharacterized, a current limitation when interpreting changes in its response. This information could provide additional utility for the tool in in vivo pharmacology studies of phyto-cannabinoid action. Methods GRABeCB2.0 was expressed in cultured HEK293 cells. Live cell confocal microscopy and high-throughput fluorescent signal measurements. Results 2-AG increased GRABeCB2.0 fluorescent signal (EC50 = 85 nM), and the cannabinoid 1 receptor (CB1R) antagonist, SR141617, decreased GRABeCB2.0 signal (SR1, IC50 = 3.3 nM), responses that mirror their known potencies at cannabinoid 1 receptors (CB1R). GRABeCB2.0 fluorescent signal also increased in response to AEA (EC50 = 815 nM), the eCB analogues 2-linoleoylglycerol and 2-oleoylglycerol (2-LG and 2-OG, EC50s = 1.5 and 1.0 μM, respectively), Δ9-tetrahydrocannabinol (Δ9-THC) and Δ8-THC (EC50s = 1.6 and 2.0 μM, respectively), and the artificial CB1R agonist, CP55,940 (CP, EC50 = 82 nM); however their potencies were less than what has been described at CB1R. Cannabidiol (CBD) did not affect basal GRABeCB2.0 fluorescent signal and yet reduced the 2-AG stimulated GRABeCB2.0 responses (IC50 = 8.8 nM). Conclusions 2-AG and SR1 modulate the GRABeCB2.0 fluorescent signal with EC50s that mirror their potencies at CB1R whereas AEA, eCB analogues, THC and CP increase GRABeCB2.0 fluorescent signal with EC50s significantly lower than their potencies at CB1R. CBD reduces the 2-AG response without affecting basal signal, suggesting that GRABeCB2.0 retains the negative allosteric modulator (NAM) property of CBD at CB1R. This study describes the pharmacological profile of GRABeCB2.0 to improve interpretation of changes in fluorescent signal in response to a series of known eCBs and CB1R ligands.
Collapse
Affiliation(s)
- Simar Singh
- Department of Pharmacology, University of Washington, Seattle, USA
- Center for Cannabis Research, University of Washington, Seattle, USA
- Center for the Neurobiology of Addiction, Pain, and Emotion, University of Washington, Seattle, USA
| | - Dennis Sarroza
- Department of Pharmacology, University of Washington, Seattle, USA
| | - Anthony English
- Department of Pharmacology, University of Washington, Seattle, USA
- Center for Cannabis Research, University of Washington, Seattle, USA
- Center for the Neurobiology of Addiction, Pain, and Emotion, University of Washington, Seattle, USA
| | - Maya McGrory
- Department of Pharmacology, University of Washington, Seattle, USA
| | - Ao Dong
- Peking University School of Life Sciences, PKU-IDG/McGovern Institute for Brain Research, Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China
| | - Larry Zweifel
- Department of Pharmacology, University of Washington, Seattle, USA
- Center for Cannabis Research, University of Washington, Seattle, USA
- Center for the Neurobiology of Addiction, Pain, and Emotion, University of Washington, Seattle, USA
- Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, USA
| | - Benjamin B. Land
- Department of Pharmacology, University of Washington, Seattle, USA
- Center for Cannabis Research, University of Washington, Seattle, USA
- Center for the Neurobiology of Addiction, Pain, and Emotion, University of Washington, Seattle, USA
| | - Yulong Li
- Peking University School of Life Sciences, PKU-IDG/McGovern Institute for Brain Research, Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China
| | - Michael R. Bruchas
- Department of Pharmacology, University of Washington, Seattle, USA
- Center for Cannabis Research, University of Washington, Seattle, USA
- Center for the Neurobiology of Addiction, Pain, and Emotion, University of Washington, Seattle, USA
- Department of Anesthesiology, School of Medicine, University of Washington, Seattle, USA
| | - Nephi Stella
- Department of Pharmacology, University of Washington, Seattle, USA
- Center for Cannabis Research, University of Washington, Seattle, USA
- Center for the Neurobiology of Addiction, Pain, and Emotion, University of Washington, Seattle, USA
- Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, USA
| |
Collapse
|
4
|
Jimenez JC, Su K, Goldberg AR, Luna VM, Biane JS, Ordek G, Zhou P, Ong SK, Wright MA, Zweifel L, Paninski L, Hen R, Kheirbek MA. Anxiety Cells in a Hippocampal-Hypothalamic Circuit. Neuron 2018; 97:670-683.e6. [PMID: 29397273 PMCID: PMC5877404 DOI: 10.1016/j.neuron.2018.01.016] [Citation(s) in RCA: 314] [Impact Index Per Article: 52.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2017] [Revised: 12/04/2017] [Accepted: 01/05/2018] [Indexed: 11/25/2022]
Abstract
The hippocampus is traditionally thought to transmit contextual information to limbic structures where it acquires valence. Using freely moving calcium imaging and optogenetics, we show that while the dorsal CA1 subregion of the hippocampus is enriched in place cells, ventral CA1 (vCA1) is enriched in anxiety cells that are activated by anxiogenic environments and required for avoidance behavior. Imaging cells defined by their projection target revealed that anxiety cells were enriched in the vCA1 population projecting to the lateral hypothalamic area (LHA) but not to the basal amygdala (BA). Consistent with this selectivity, optogenetic activation of vCA1 terminals in LHA but not BA increased anxiety and avoidance, while activation of terminals in BA but not LHA impaired contextual fear memory. Thus, the hippocampus encodes not only neutral but also valence-related contextual information, and the vCA1-LHA pathway is a direct route by which the hippocampus can rapidly influence innate anxiety behavior.
Collapse
Affiliation(s)
- Jessica C Jimenez
- Departments of Neuroscience, Psychiatry & Pharmacology, Columbia University, New York, NY, USA; Division of Integrative Neuroscience, Department of Psychiatry, New York State Psychiatric Institute, New York, NY, USA
| | - Katy Su
- Departments of Neuroscience, Psychiatry & Pharmacology, Columbia University, New York, NY, USA; Division of Integrative Neuroscience, Department of Psychiatry, New York State Psychiatric Institute, New York, NY, USA
| | - Alexander R Goldberg
- Departments of Neuroscience, Psychiatry & Pharmacology, Columbia University, New York, NY, USA; Division of Integrative Neuroscience, Department of Psychiatry, New York State Psychiatric Institute, New York, NY, USA
| | - Victor M Luna
- Departments of Neuroscience, Psychiatry & Pharmacology, Columbia University, New York, NY, USA; Division of Integrative Neuroscience, Department of Psychiatry, New York State Psychiatric Institute, New York, NY, USA
| | - Jeremy S Biane
- Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA
| | - Gokhan Ordek
- Departments of Neuroscience, Psychiatry & Pharmacology, Columbia University, New York, NY, USA; Division of Integrative Neuroscience, Department of Psychiatry, New York State Psychiatric Institute, New York, NY, USA
| | - Pengcheng Zhou
- Center for the Neural Basis of Cognition and Machine Learning Department, Carnegie Mellon University, Pittsburgh, PA, USA; Departments of Statistics and Neuroscience, Grossman Center for the Statistics of Mind, Center for Theoretical Neuroscience, Kavli Institute for Brain Science, and NeuroTechnology Center, Columbia University, New York, NY, USA
| | - Samantha K Ong
- Departments of Neuroscience, Psychiatry & Pharmacology, Columbia University, New York, NY, USA; Division of Integrative Neuroscience, Department of Psychiatry, New York State Psychiatric Institute, New York, NY, USA
| | - Matthew A Wright
- Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA
| | - Larry Zweifel
- Department of Pharmacology, University of Washington, Seattle, WA 98105, USA; Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA 98105, USA
| | - Liam Paninski
- Departments of Statistics and Neuroscience, Grossman Center for the Statistics of Mind, Center for Theoretical Neuroscience, Kavli Institute for Brain Science, and NeuroTechnology Center, Columbia University, New York, NY, USA
| | - René Hen
- Departments of Neuroscience, Psychiatry & Pharmacology, Columbia University, New York, NY, USA; Division of Integrative Neuroscience, Department of Psychiatry, New York State Psychiatric Institute, New York, NY, USA.
| | - Mazen A Kheirbek
- Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA; Neuroscience Graduate Program, University of California, San Francisco, San Francisco, CA, USA; Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA; Kavli Institute for Fundamental Neuroscience, University of California, San Francisco, San Francisco, CA, USA; Center for Integrative Neuroscience, University of California, San Francisco, San Francisco, CA, USA.
| |
Collapse
|
5
|
Wall VZ, Parker JG, Fadok JP, Darvas M, Zweifel L, Palmiter RD. A behavioral genetics approach to understanding D1 receptor involvement in phasic dopamine signaling. Mol Cell Neurosci 2010; 46:21-31. [PMID: 20888914 DOI: 10.1016/j.mcn.2010.09.011] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2010] [Accepted: 09/23/2010] [Indexed: 11/28/2022] Open
Abstract
Dopamine-producing neurons fire with both basal level tonic patterns and phasic bursts. Varying affinities of the five dopamine receptors have led to a hypothesis that higher affinity receptors are primarily activated by basal level tonic dopamine, while lower affinity receptors may be tuned to be sensitive to higher levels caused by phasic bursts. Genetically modified mice provide a method to begin to probe this hypothesis. Here we discuss three mouse models. Dopamine-deficient mice were used to determine which behaviors require dopamine. These behaviors were then analyzed in mice lacking D1 receptors and in mice with reduced phasic dopamine release. Comparison of the latter two mouse models revealed a similar failure to learn about and respond normally to cues that indicate either a positive or negative outcome, giving support to the hypothesis that phasic dopamine release and the D1 receptor act in the same pathway. However, the D1 receptor likely has additional roles beyond those of phasic dopamine detection, because D1 receptor knockout mice have deficits in addition to what has been observed in mice with reduced phasic dopamine release.
Collapse
Affiliation(s)
- Valerie Z Wall
- Howard Hughes Medical Institute, University of Washington, Seattle, Washington 98195, USA
| | | | | | | | | | | |
Collapse
|
6
|
Zweifel L, Büni T, Rühli FJ. Evidence-based palaeopathology: meta-analysis of PubMed-listed scientific studies on ancient Egyptian mummies. Homo 2009; 60:405-27. [PMID: 19744651 DOI: 10.1016/j.jchb.2009.07.002] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/21/2009] [Accepted: 07/13/2009] [Indexed: 11/25/2022]
Abstract
There is a plethora of published scientific studies on ancient Egyptian mummies. Surprisingly, hitherto there is no systematic review of this research, which would help to assess the quality of this vast body of published literature and thus to increase "evidence" in palaeopathological research. The aim of this study was to review all PubMed-listed scientific studies performed on Ancient Egyptian mummies. A total of 131 studies were found in the database for the selected time period, 1977-2005. Our "meta-analysis" showed that the number of publications per year varies enormously. The majority of mummies examined date to the third intermediate and Ptolemaic periods; data from other time periods were lacking. Identification of the cause of death and (14)C-dating of the mummy or funeral goods were rarely addressed. There was a tendency towards an increased use of non-invasive examination methods in more modern times. Our meta-analysis addressed both scientific content (e.g. palaeopathological findings/examination methods) and publication issues (e.g. location of the first author or year of publication) in these studies. Based on our experience, we recommend some minimum publication standards for palaeopathologic studies on ancient mummies, which shall improve evidence-based research in palaeopathology in general.
Collapse
Affiliation(s)
- L Zweifel
- Institute of Anatomy, University of Zurich, Zurich, Switzerland
| | | | | |
Collapse
|
7
|
Wand G, Levine M, Zweifel L, Schwindinger W, Abel T. The cAMP-protein kinase A signal transduction pathway modulates ethanol consumption and sedative effects of ethanol. J Neurosci 2001; 21:5297-303. [PMID: 11438605 PMCID: PMC6762861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023] Open
Abstract
Ethanol and other drugs of abuse modulate cAMP-PKA signaling within the mesolimbic reward pathway. To understand the role of the cAMP-PKA signal transduction in mediating the effects of ethanol, we have studied ethanol consumption and the sedative effects of ethanol in three lines of genetically modified mice. We report that mice with the targeted disruption of one Gsalpha allele as well as mice with reduced neuronal PKA activity have decreased alcohol consumption compared with their wild-type littermates. Genetic reduction of cAMP-PKA signaling also makes mice more sensitive to the sedative effects of ethanol, although plasma ethanol concentrations are unaffected. In contrast, mice with increased adenylyl cyclase activity resulting from the transgenic expression of a constitutively active form of Gsalpha in neurons within the forebrain are less sensitive to the sedative effects of ethanol. Thus, the cAMP-PKA signal transduction pathway is critical in modulating sensitivity to the sedative effects of ethanol as well as influencing alcohol consumption.
Collapse
Affiliation(s)
- G Wand
- Departments of Medicine, Psychiatry, and Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
| | | | | | | | | |
Collapse
|